{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:44Z","timestamp":1789699064591,"version":"4.0.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched four electronic databases to identify randomized controlled trials and cohort studies comparing the impact of prasugrel and ticagrelor on PR in patients with ACS. We performed group analyses according to three detection methods, drug dose [loading dose (LD) and maintenance dose (MTD)] and LD effect time, and assessed the robustness of the results through sensitivity analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five studies with 5,098 patients were eligible. After LD, the incidence of high on-treatment platelet reactivity (HTPR) of ticagrelor was significantly lower than that of prasugrel within 6\u201318 h based on vasodilator-stimulated phosphoprotein (VASP) test [RR = 0.25 (0.07, 0.85), <jats:italic>P<\/jats:italic> = 0.03], there was no significant difference between ticagrelor and prasugrel in the following results: platelets inhibitory effect within 24\u201348 h based on VerifyNow P2Y12 (VN) assay (<jats:italic>P<\/jats:italic> = 0.11) and VASP test (<jats:italic>P<\/jats:italic> = 0.20), and the incidence of HTPR within 2\u20136 h based on VN assay (<jats:italic>P<\/jats:italic> = 0.57) and within 24\u201348 h based on VN assay (<jats:italic>P<\/jats:italic> = 0.46) and VASP test (<jats:italic>P<\/jats:italic> = 0.72), the incidence of low on-treatment platelet reactivity (LTPR) within 6\u201318 h based on VASP test (<jats:italic>P<\/jats:italic> = 0.46) and 48 h based on VN assay (<jats:italic>P<\/jats:italic> = 0.97) and VASP test (<jats:italic>P<\/jats:italic> = 0.73). After MTD, the platelet inhibitory effect of ticagrelor was stronger than that of prasugrel based on VN assay [WMD = \u221241.64 (\u221247.16, \u221236.11), <jats:italic>P<\/jats:italic> &amp;lt; 0.00001]and VASP test [WMD = \u22129.10 (\u221213.88, \u22124.32), <jats:italic>P<\/jats:italic> = 0.0002], the incidence of HTPR of ticagrelor was significantly lower than that of prasugrel based on VN assay [RR = 0.05 (0.02, 0.16), <jats:italic>P<\/jats:italic> &amp;lt; 0.00001], the incidence of LTPR of ticagrelor was significantly higher than prasugrel based on VN assay [RR = 6.54 (4.21, 10.14), <jats:italic>P<\/jats:italic> &amp;lt; 0.00001] and VASP test [RR = 2.65 (1.78, 3.96), <jats:italic>P<\/jats:italic> &amp;lt; 0.00001], the results of Multiple Electrode Aggregometry (MEA) test was inconsistent with the other two detection methods in platelet inhibitory effect and the incidence of HTPR and LTPR. There was no significant difference between ticagrelor and prasugrel in the following clinical outcomes: all-cause death (<jats:italic>P<\/jats:italic> = 0.86), cardiovascular death (<jats:italic>P<\/jats:italic> = 0.49), myocardial infarction (<jats:italic>P<\/jats:italic> = 0.67), stroke (<jats:italic>P<\/jats:italic> = 0.51), target vessel revascularization (<jats:italic>P<\/jats:italic> = 0.51), stent thrombosis (<jats:italic>P<\/jats:italic> = 0.90), TIMI major bleeding (<jats:italic>P<\/jats:italic> = 0.86) and bleeding BARC type \u2265 2 (<jats:italic>P<\/jats:italic> = 0.77). The risk of bleeding BARC type 1 of ticagrelor was significantly higher than prasugrel [RR = 1.44 (1.03, 2.02), <jats:italic>P<\/jats:italic> = 0.03].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Compared with prasugrel, ticagrelor might have a stronger platelet inhibition effect, with a lower incidence of HTPR and a higher incidence of LTPR and bleeding BARC type 1, while there might be no significant difference in the risk of thrombosis\/ischemic, bleeding BARC Type \u2265 2 and TIMI major bleeding. A higher incidence of LTPR might indicate a higher risk of bleeding BARC type 1. The results of VN assay were consistent with that of VASP test, and not with the MEA test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42022304205<\/jats:ext-link>, identifier: CRD42022304205.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.905607","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:45:16Z","timestamp":1654839916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Lulu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuerong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ahj.2008.06.004","article-title":"Pharmacology of emerging novel platelet inhibitors","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy855","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.rec.2017.11.020","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8703627","DOI":"10.1155\/2020\/8703627","article-title":"The role of clopidogrel in 2020: a reappraisal","volume":"2020","author":"Patti","year":"2020","journal-title":"Cardiovasc Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40262-020-00864-4","article-title":"Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists","volume":"59","author":"Schilling","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules26071987","article-title":"The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an asian population with coronary heart disease (CHD)","volume":"26","author":"Akkaif","year":"2021","journal-title":"Molecules."},{"key":"B8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vph.2015.10.005","article-title":"On-treatment platelet reactivity: state of the art and perspectives","volume":"77","author":"Marcucci","year":"2016","journal-title":"Vascul Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2147\/DDDT.S196535","article-title":"Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis","volume":"13","author":"Fan","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/FJC.0000000000000451","article-title":"Meta-analysis of comparison of the newer P2Y12 inhibitors (Oral Preparation or Intravenous) to clopidogrel in patients with acute coronary syndrome","volume":"69","author":"Zhang","year":"2017","journal-title":"J Cardiovasc Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/jpm11050323","article-title":"An ex vivo and in silico study providing insights into the interplay of circulating mirnas level, platelet reactivity and thrombin generation: looking beyond traditional pharmacogenetics","volume":"11","author":"Garcia","year":"2021","journal-title":"J Pers Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12872-020-01603-0","article-title":"Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis","volume":"20","author":"Wen","year":"2020","journal-title":"BMC Cardiovasc Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med."},{"key":"B19","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane\n            HigginsJPT\n            ThomasJ\n            ChandlerJ\n            CumpstonM\n            LiT\n            PageMJ\n          2021"},{"key":"B20","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute\n            WellsGA\n            SheaB\n            O'ConnellD\n            PetersonJ\n            WelchV\n            LososM\n          2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11239-014-1119-9","article-title":"Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction","volume":"39","author":"Perl","year":"2015","journal-title":"J Thromb Thrombolysis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.resuscitation.2014.02.004","article-title":"High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest","volume":"85","author":"Ibrahim","year":"2014","journal-title":"Resuscitation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.thromres.2015.04.014","article-title":"Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a real World registry","volume":"135","author":"Motovska","year":"2015","journal-title":"Thromb Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3904\/kjim.2015.30.5.620","article-title":"A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome","volume":"30","author":"Lee","year":"2015","journal-title":"Korean J Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.3390\/jcm10122699","article-title":"Pharmacodynamics and outcomes of a de-escalation strategy with half-dose prasugrel or ticagrelor in east asians patients with acute coronary syndrome: results from HOPE-TAILOR trial","volume":"10","author":"Jin","year":"2021","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2016.12.173","article-title":"P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: analysis from the SAMPA randomized trial","volume":"230","author":"Guimar\u00e3es","year":"2017","journal-title":"Int J Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.thromres.2019.01.021","article-title":"High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"175","author":"Ferreiro","year":"2019","journal-title":"Thromb Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-015-0232-1","article-title":"Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study","volume":"14","author":"Alexopoulos","year":"2015","journal-title":"Cardiovasc Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijcard.2014.04.208","article-title":"Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor","volume":"35","author":"Lhermusier","year":"2014","journal-title":"Eur Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1160\/TH13-05-0384","article-title":"Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome a pharmacodynamic randomised study","volume":"111","author":"Laine","year":"2014","journal-title":"Thromb Haemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3109\/09537104.2014.959914","article-title":"COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study","volume":"26","author":"Laine","year":"2015","journal-title":"Platelets."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.ijcard.2013.10.043","article-title":"Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison","volume":"170","author":"Deharo","year":"2013","journal-title":"Int J Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events","volume":"112","author":"Alexopoulos","year":"2014","journal-title":"Thromb Haemost."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2337\/dc12-2510","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes","volume":"36","author":"Alexopoulos","year":"2013","journal-title":"Diabetes Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijcard.2014.07.019","article-title":"Ticagrelor effectiveness overestimated by VASP index Platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests","volume":"176","author":"Dillinger","year":"2014","journal-title":"Int J Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1111\/eci.13102","article-title":"Platelet reactivity patterns in patients treated with dual antiplatelet therapy","volume":"49","author":"Winter","year":"2019","journal-title":"Eur J Clin Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/rth2.12213","article-title":"Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors","volume":"3","author":"Wadowski","year":"2019","journal-title":"Res Pract Thromb Haemostasis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/1074248420968706","article-title":"Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors","volume":"26","author":"Wadowski","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3109\/09537104.2015.1095874","article-title":"Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor","volume":"27","author":"Siller-Matula","year":"2016","journal-title":"Platelets."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e13304","DOI":"10.1111\/eci.13304","article-title":"Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients","volume":"50","author":"Gager","year":"2020","journal-title":"Eur J Clin Investig"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3390\/jcm11092480","article-title":"Differences in optimal platelet reactivity after potent P2Y12 inhibitor treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"11","author":"Song","year":"2022","journal-title":"J Clin Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1253\/circj.CJ-15-0270","article-title":"Comparison of prasugrel and ticagrelor antiplatelet effects in korean patients presenting with st-segment elevation myocardial infarction","volume":"79","author":"Lee","year":"2015","journal-title":"Circul J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.bjp.0703045","article-title":"A(2A) adenosine receptors in human peripheral blood cells","volume":"129","author":"Gessi","year":"2000","journal-title":"Br J Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/jth.13997","article-title":"Platelet function testing: dead or alive","volume":"16","author":"Helten","year":"2018","journal-title":"J Thromb Haemost."},{"key":"B50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/09537104.2013.840363","article-title":"Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials","volume":"25","author":"Lemesle","year":"2014","journal-title":"Platelets."},{"key":"B51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jcin.2013.04.009","article-title":"Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs)","volume":"6","author":"Cuisset","year":"2013","journal-title":"JACC Cardiovasc Interv."},{"key":"B54","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.amjcard.2010.11.025","article-title":"Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study)","volume":"107","author":"Patti","year":"2011","journal-title":"Am J Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.905607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:45:23Z","timestamp":1654839923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.905607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":55,"alternative-id":["10.3389\/fcvm.2022.905607"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.905607","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"905607"}}